Analysts Anticipate XOMA Corp (XOMA) Will Post Earnings of -$0.13 Per Share

Brokerages expect XOMA Corp (NASDAQ:XOMA) to post ($0.13) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for XOMA’s earnings, with the lowest EPS estimate coming in at ($0.54) and the highest estimate coming in at $0.12. XOMA reported earnings per share of ($0.46) in the same quarter last year, which would suggest a positive year-over-year growth rate of 71.7%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, May 8th.

According to Zacks, analysts expect that XOMA will report full year earnings of ($1.41) per share for the current year, with EPS estimates ranging from ($1.75) to ($0.75). For the next year, analysts anticipate that the business will post earnings of ($1.41) per share, with EPS estimates ranging from ($2.33) to ($0.74). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for XOMA.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.14. The firm had revenue of $1.69 million for the quarter, compared to analysts’ expectations of $1.30 million. XOMA had a negative net margin of 251.80% and a negative return on equity of 175.48%.

Several analysts recently issued reports on the stock. ValuEngine upgraded shares of XOMA from a “sell” rating to a “hold” rating in a report on Monday, April 1st. HC Wainwright set a $30.00 price objective on shares of XOMA and gave the company a “buy” rating in a report on Friday, April 12th. Wedbush restated a “buy” rating and issued a $26.00 price objective on shares of XOMA in a report on Monday, March 11th. Finally, Zacks Investment Research upgraded shares of XOMA from a “sell” rating to a “hold” rating in a report on Saturday, March 9th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. XOMA currently has a consensus rating of “Hold” and a consensus target price of $24.82.

Shares of XOMA opened at $12.29 on Tuesday. The stock has a market capitalization of $114.80 million, a P/E ratio of -7.69 and a beta of 2.45. XOMA has a 12-month low of $11.02 and a 12-month high of $25.99. The company has a debt-to-equity ratio of 1.15, a quick ratio of 8.35 and a current ratio of 8.35.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its stake in XOMA by 12.4% during the fourth quarter. BlackRock Inc. now owns 508,672 shares of the biotechnology company’s stock worth $6,434,000 after purchasing an additional 56,130 shares during the period. Opaleye Management Inc. increased its stake in XOMA by 25.0% during the fourth quarter. Opaleye Management Inc. now owns 400,000 shares of the biotechnology company’s stock worth $5,060,000 after purchasing an additional 80,000 shares during the period. Fosun International Ltd purchased a new stake in XOMA during the fourth quarter worth about $3,842,000. Vanguard Group Inc increased its stake in XOMA by 1.0% during the third quarter. Vanguard Group Inc now owns 311,093 shares of the biotechnology company’s stock worth $5,466,000 after purchasing an additional 3,167 shares during the period. Finally, Vanguard Group Inc. increased its stake in XOMA by 1.0% during the third quarter. Vanguard Group Inc. now owns 311,093 shares of the biotechnology company’s stock worth $5,466,000 after purchasing an additional 3,167 shares during the period. Hedge funds and other institutional investors own 48.00% of the company’s stock.

About XOMA

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

Read More: What is the LIBOR?

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.